1. Home
  2. PEBK vs MGNX Comparison

PEBK vs MGNX Comparison

Compare PEBK & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp of North Carolina Inc.

PEBK

Peoples Bancorp of North Carolina Inc.

HOLD

Current Price

$44.23

Market Cap

218.4M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.59

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBK
MGNX
Founded
1912
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.4M
220.6M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
PEBK
MGNX
Price
$44.23
$4.59
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
27.8K
662.0K
Earning Date
04-20-2026
05-08-2026
Dividend Yield
2.58%
N/A
EPS Growth
21.48
N/A
EPS
0.80
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
$53.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.81
$1.19
52 Week High
$45.78
$4.64

Technical Indicators

Market Signals
Indicator
PEBK
MGNX
Relative Strength Index (RSI) 61.63 65.09
Support Level $38.84 $1.49
Resistance Level $45.78 N/A
Average True Range (ATR) 1.27 0.29
MACD -0.06 0.02
Stochastic Oscillator 62.82 69.03

Price Performance

Historical Comparison
PEBK
MGNX

About PEBK Peoples Bancorp of North Carolina Inc.

Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: